**Editor’s Note:** This article was curated and enhanced for our readers.
*Source: {feed_title}*
—
## Unlocking the Brain: China’s Leap into Non-Invasive BCI with Gestala
The frontier of brain-computer interfaces (BCIs) is rapidly expanding, with an exciting new chapter unfolding in China. A burgeoning industry is witnessing innovative companies striving to bridge the gap between human thought and technology, and the latest entrant is poised to revolutionize how we interact with our own minds – without the need for invasive surgery.
Enter Gestala, a newly established firm headquartered in Chengdu, with strategic outposts in Shanghai and Hong Kong. This ambitious startup is charting a course to access the brain’s intricate networks through sophisticated ultrasound technology, initially for stimulation and eventually for direct neural readings. This groundbreaking approach, championed by CEO and cofounder Phoenix Peng, marks a significant departure from traditional implant-based BCIs.
### Gestala’s Vision: Tapping the Brain with Sound Waves
Gestala isn’t operating in a vacuum. It represents the second major player in recent weeks to announce intentions of harnessing ultrasound for brain interfacing. Earlier this month, the tech world buzzed with news of OpenAI’s substantial investment in Merge Labs, another ultrasound-focused BCI startup co-founded by OpenAI CEO Sam Altman, alongside other industry titans and researchers from Forest Neurotech, a California-based non-profit.
While most commonly associated with medical imaging – like monitoring fetal development or visualizing internal organs and blood flow – ultrasound’s therapeutic potential is immense and increasingly recognized. Depending on its intensity and focus, high-frequency sound waves can precisely target and even destroy abnormal tissues, such as blood clots or cancerous cells. Crucially, it can also modulate neural activity without requiring surgical intervention. This non-invasive capability has already paved the way for focused ultrasound treatments approved for conditions like Parkinson’s disease, uterine fibroids, and certain types of tumors.
## From Clinic to Couch: Gestala’s Phased Approach to Brain Health
Gestala’s strategic roadmap outlines a phased development of its ultrasound BCI technology, starting with therapeutic applications and progressively moving towards broader accessibility.
### Addressing Chronic Pain: The First Frontier
The immediate goal for Gestala is to develop a device specifically engineered to deliver focused ultrasound to the brain for the treatment of chronic pain. Early pilot studies have yielded promising results, demonstrating that stimulating the anterior cingulate cortex – a brain region intricately linked to the emotional processing of pain – can significantly reduce pain intensity for up to a week.
Peng reveals that Gestala’s inaugural device will be a stationary, benchtop unit, necessitating patients to visit a clinic for treatment. The company is already engaged in discussions with several hospitals across China, exploring opportunities to pilot and test this innovative technology.
### The Future is Wearable: Home-Based Therapy
Looking ahead, Gestala envisions a second-generation device: a wearable helmet. This evolution will empower patients to receive treatment in the comfort of their homes, under the remote guidance of a physician. Beyond its initial focus on chronic pain, Gestala plans to systematically expand its therapeutic scope to encompass a wide array of conditions. These include debilitating mental health challenges like depression, alongside stroke rehabilitation, Alzheimer’s disease, and various sleep disorders.
## Beyond Stimulation: The Ambitious Leap to Brain Reading
Like its counterpart, Merge Labs, Gestala harbors an even grander ambition: to leverage ultrasound not just for stimulating, but also for *reading* brain activity. The ultimate aspiration is a sophisticated device capable of detecting specific brain states associated with conditions like chronic pain or depression. Upon identification, this intelligent system would then deliver precise therapeutic stimulation to the exact neural regions exhibiting abnormal activity, fostering healthier neural functions rather than simply “enhancing” human capabilities.
Most existing BCIs, including high-profile projects like Neuralink, operate by detecting the electrical signals generated by neurons. Gestala’s ultrasound-based interface, however, would employ an entirely different mechanism: it would measure subtle changes in the brain’s blood flow. This distinction is crucial, as Phoenix Peng, who previously served as CEO and cofounder of Shanghai-based NeuroXess (a company developing electrical signal-based brain implants), elaborates. Peng parted ways with NeuroXess last year to dedicate his efforts to Gestala, driven by a compelling insight. “The electrical brain-computer interface only records from a part of the brain; for instance, the motor cortex,” Peng explains. “Ultrasound, it seems like, can provide us with the capability to access the whole brain.”
## The Minds Behind Gestala: A Fusion of Innovation
The pioneering spirit of Gestala is fueled by a powerful combination of scientific expertise and entrepreneurial acumen. Phoenix Peng brings a deep understanding of BCI technology and its medical applications. His cofounder is Tianqiao Chen, the visionary behind the immensely successful online gaming company Shanda Interactive Entertainment. Chen is also the founder of the California-based Tianqiao and Chrissy Chen Institute, a non-profit dedicated to advancing neuroscience research, further underscoring his commitment to the field.
The company’s name, Gestala, draws inspiration from Gestalt psychology, a German school of thought famously encapsulated by the adage: “the whole is greater than the sum of its parts” – a fitting philosophy for a technology aiming for comprehensive brain access.
## Navigating the Challenges: The Road Ahead for Ultrasound BCIs
While the promise of ultrasound BCIs is immense, the path forward is not without its complexities. Maximilian Riesenhuber, a distinguished professor of neuroscience and co-director of the Center for Neuroengineering at Georgetown University, highlights the formidable challenges involved in extracting meaningful information from the brain using ultrasound. Delivering targeted ultrasound for therapeutic purposes is significantly less complex than accurately “reading” neural activity. The human skull, a protective barrier, inherently weakens and distorts ultrasound signals. To date, researchers have only managed to interpret neural activity with ultrasound by surgically removing a portion of the skull, creating an acoustic “window” into the brain.
Despite these hurdles, Gestala’s ambitious pursuit represents a pivotal moment in BCI development. Their commitment to non-invasive methods, coupled with a clear, phased approach to therapeutic and diagnostic applications, positions them at the forefront of a potentially transformative era in brain health and human-technology interaction. The silent waves of ultrasound may well be the key to unlocking the brain’s deepest secrets.